Cite
HARVARD Citation
Lin, K. et al. (n.d.). 2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. European journal of cancer. pp. S531-S532. [Online].